- Home
- OFS vs VOR Comparison
OFS vs VOR Comparison
Compare OFS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- VOR
- Stock Information
- Founded
- OFS 2001
- VOR 2015
- Country
- OFS United States
- VOR United States
- Employees
- OFS N/A
- VOR N/A
- Industry
- OFS Finance/Investors Services
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- VOR Health Care
- Exchange
- OFS Nasdaq
- VOR Nasdaq
- Market Cap
- OFS 127.4M
- VOR 134.8M
- IPO Year
- OFS 2012
- VOR 2021
- Fundamental
- Price
- OFS $9.39
- VOR $0.64
- Analyst Decision
- OFS
- VOR Strong Buy
- Analyst Count
- OFS 0
- VOR 7
- Target Price
- OFS N/A
- VOR $9.43
- AVG Volume (30 Days)
- OFS 89.3K
- VOR 251.4K
- Earning Date
- OFS 05-01-2025
- VOR 05-08-2025
- Dividend Yield
- OFS 14.39%
- VOR N/A
- EPS Growth
- OFS N/A
- VOR N/A
- EPS
- OFS 2.12
- VOR N/A
- Revenue
- OFS $47,964,000.00
- VOR N/A
- Revenue This Year
- OFS N/A
- VOR N/A
- Revenue Next Year
- OFS N/A
- VOR N/A
- P/E Ratio
- OFS $4.45
- VOR N/A
- Revenue Growth
- OFS N/A
- VOR N/A
- 52 Week Low
- OFS $7.75
- VOR $0.62
- 52 Week High
- OFS $10.14
- VOR $2.23
- Technical
- Relative Strength Index (RSI)
- OFS 59.82
- VOR 25.90
- Support Level
- OFS $8.88
- VOR $0.62
- Resistance Level
- OFS $9.52
- VOR $0.93
- Average True Range (ATR)
- OFS 0.27
- VOR 0.07
- MACD
- OFS -0.02
- VOR -0.01
- Stochastic Oscillator
- OFS 60.26
- VOR 5.03
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.